Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA7 | P43166 | 5/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463075 | 1.00 | CA1 (0.53) | CA1CA2CA9CA12CA7 | |
| SCHEMBL20802853 | 0.92 | CA1 (0.53) | CA1CA2CA9CA12CA7 | |
| SCHEMBL25341252 | 0.90 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL30448096 | 0.90 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1538335 | 0.85 | CA12 (0.63) | CA1CA2CA9CA12CA7 | |
| SCHEMBL168324 | 0.85 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL21438937 | 0.85 | CCR6 (0.47) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2316462 | 0.83 | SOS1 (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL17239465 | 0.83 | ABL1 (0.45) | CA1CA2CA9CA12CA7 | |
| SCHEMBL747498 | 0.83 | CA1 (0.49) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751200-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-110114071-B | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-3534903-B1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2022-08-03 | — | — | EP | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2008086857-A1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| WO-2007139955-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-0805681-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0805681-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022775-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | CA1 3458/4885CA2 3150/4885CA9 2266/4885 |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | HSP90AB1, HSP90AA1, HSP90AB2P | CA1 4819/4885CA2 4321/4885CA9 4562/4885 |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | CA1 3458/4885CA2 3150/4885CA9 2266/4885 |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | CA1 3458/4885CA2 3150/4885CA9 2266/4885 |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | CA1 4328/4885CA2 4006/4885CA9 2269/4885 |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | CA1 3458/4885CA2 3150/4885CA9 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.